Platinum agents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines

Robson, Helen; Meyer, S.; Sm, Shalet; Anderson, Elizabeth; Sa, Roberts; Eden, O. B.

doi:10.1002/mpo.10076

Cited by 37 publications

(29 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CBDCA is a synthesized platinum compound with fewer side effects as compared to those of cisplatin. Preclinical data of CBDCA against osteosarcoma was rather indicative (Bergman et al, 1996;Crnalic et al, 1996;Robson et al, 2002) of its ability to induce regression of osteosarcoma. The efficacy of CBDCA was comparable to cisplatin in treatment of several solid tumors, especially in adults (Lokich and Anderson, 1998).…”

Section: Discussionmentioning

confidence: 99%

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Choeyprasert¹,

Natesirinilkul²,

Charoenkwan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Osteosarcoma is the most common primary bone tumor in childhood and adolescence. Carboplatin, a platinum-derived agent, is used as neoadjuvant chemotherapy for pediatric osteosarcoma because of its anti-tumor activity and had low toxicity as compared to cisplatin. Objective: To determine demographic data, prognostic factors and outcome of childhood osteosarcoma treated with a carboplatin-based chemotherapeutic protocol at Chiang Mai University. Method: A retrospective analysis was conducted on 34 osteosarcoma patients aged less than 18 years and treated between 2003 and 2011. Results: Overall limb-salvage and amputation rates were 23.5% and 70.6%, respectively. With the mean follow-up time of 29.5 months (1.5-108.9), the Kaplan-Meier analysis for 3-year disease-free survival (DFS) and 3-year overall survival (OS) were 20.2±7.7% and 47.1±9.5% respectively. Patients who had initial pulmonary metastasis were at significantly greater risk for developing recurrence (p=0.02, OR=7; 1.2-40.1) and had a tendency to have lower 3-year OS compared to those without initial pulmonary metastasis (28.1±13%, 63.1±12.3%, respectively, p=0.202). On univariate analysis, age at diagnosis >14 years and patients who were declined surgery were significantly associated with lower 3-year OS (p=0.008 and <0.05, respectively). However, age at diagnosis, sex, tumor size and histological subtypes were not found to significantly affect recurrence or survival. Conclusions: In our study, the survival rate was far lower than those reported from developed countries. These might indicate the ineffectiveness of carboplatin in combination with doxorubicin as frontline treatment of pediatric osteosarcoma, especially in those with initial pulmonary metastasis. Refinement in risk and treatment stratification and dose intensification for pediatric osteosarcoma constitutes a future challenge to improve outcomes, especially in metastatic patients who may need a more intensive regimen.

show abstract

Section: Discussionmentioning

confidence: 99%

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Choeyprasert¹,

Natesirinilkul²,

Charoenkwan³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The variable response of osteosarcoma cell lines to conventional chemotherapeutical agents has been described before in several reports. Robson et al 24 showed that cisplatin has no cytotoxic effect on U-2 osteosarcoma cells at a concentration of 20 mM, while HOS and MG-63 cells showed an ED 50 at 9.0 and 12.2 mM, respectively. Gomes et al 25 showed that doxorubicin was able to significantly induce cell death in SAOS-2 cells, but no effect was observed for HOS and U-2 OS cells.…”

Section: Discussionmentioning

confidence: 99%

Taurine chloramine induces apoptosis in human osteosarcoma cell lines

Pilz

Holinka

Vavken

et al. 2012

Journal Orthopaedic Research

View full text Add to dashboard Cite

Although combination of surgery with chemotherapy has noticeably improved the survival rate of osteosarcoma patients, the application of anticancer drugs is still associated with significant adverse reactions, for instance acquisition of drug-resistant phenotypes, necessitating the development of new chemotherapeutical agents. Therefore, the aim of this study was to research, if taurine chloramine (NCT) induces apoptosis in the osteosarcoma cell lines HOS, MG-63, and SAOS-2. Proliferation of osteosarcoma cells was detected with the ''EZ4U Cell Proliferation and Cyotoxicity Assay'' showing a time-and dose-dependent cytotoxic effect of NCT on these cell lines. After 3 h of incubation all cell lines showed significantly less cells at 5.5 mM NCT solutions, after 6 h at concentrations of 1.1 and 2.2 mM. Acridine-orange fluorescence nuclear staining showed characteristic features of apoptosis. DNA fragmentation was detected via ELISA, showing significant results for HOS and MG-63 after 6 h at an NCT concentration of 3.3 mM. Results of JC-1 mitochondrial FACS analysis presented a significant increase in apoptotic cells after 6 h at 3.3 mM for the tested cell lines. Summarized, the results of this study indicate that NCT is a promising agent in osteosarcoma therapy. ß

show abstract

“…Other authors have suggested that the complexes have a square planar structure and are much more inert [29] or that the loss of methanol from the ligands causes esterification of the carboxyl groups present in the fungal cell walls [30]. The inhibition values obtained from the Pt(II) complexes could arise from deeper effects on the DNA replication and transcription machinery of the cell since they are known to bind to the internal groove of the DNA helix and interfering with normal function of arresting DNA polymerase [31,32]. This effect usually acts as a trigger leading to apoptosis.…”

Section: Antifungal Activity Of N-benzoyl-n-alkylthioureides and N-bementioning

confidence: 99%

“…The compounds were tested in the presence of 500 ppm of ligands 29, and 30 and their Ni(II) complexes (31) and (32). Ni(II) complexes (31) and (32) have been characterized by X-ray crystallography by del Campo et al in 2002 [18]. In general, inhibition by the ligands was higher than that of the complexes, while the N,N-diethyl substituents had a greater influence on the antifungal activity than the N-morpholino substituent (see Schemes 3 and 4).…”

Section: Antifungal Activity Of N-benzoyl-nnmentioning

confidence: 99%

See 1 more Smart Citation

Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents

Rodríguez-Fernández

Manzano

Benito

et al. 2005

Journal of Inorganic Biochemistry

134

View full text Add to dashboard Cite

Platinum agents in the treatment of osteosarcoma: Efficacy of cisplatin vs. carboplatin in human osteosarcoma cell lines

Abstract: Our findings suggest that CBDCA at a two- to four-fold higher concentration than cDDP has potential therapeutic activity in platinum sensitive osteosarcomas, particularly when cDDP cytotoxicity compromises therapeutic efficacy.

Cited by 37 publications

References 42 publications

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Carboplatin and Doxorubicin in Treatment of Pediatric Osteosarcoma: A 9-year Single Institute Experience in the Northern Region of Thailand

Taurine chloramine induces apoptosis in human osteosarcoma cell lines

Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents

Contact Info

Product

Resources

About